RxSight, Inc. (NASDAQ:RXST) Shares Purchased by Lazard Asset Management LLC

Lazard Asset Management LLC raised its position in RxSight, Inc. (NASDAQ:RXST - Free Report) by 156.2% during the 4th quarter, according to its most recent disclosure with the SEC. The fund owned 263,439 shares of the company's stock after purchasing an additional 160,598 shares during the period. Lazard Asset Management LLC owned about 0.65% of RxSight worth $9,057,000 at the end of the most recent reporting period.

Other large investors also recently bought and sold shares of the company. Barclays PLC boosted its stake in shares of RxSight by 389.8% during the third quarter. Barclays PLC now owns 58,786 shares of the company's stock valued at $2,906,000 after acquiring an additional 46,783 shares during the last quarter. Global Retirement Partners LLC acquired a new stake in shares of RxSight during the fourth quarter valued at $69,000. Vanguard Group Inc. boosted its stake in shares of RxSight by 4.2% during the fourth quarter. Vanguard Group Inc. now owns 2,383,548 shares of the company's stock valued at $81,946,000 after acquiring an additional 96,464 shares during the last quarter. Bank of New York Mellon Corp boosted its stake in shares of RxSight by 10.0% during the fourth quarter. Bank of New York Mellon Corp now owns 102,882 shares of the company's stock valued at $3,537,000 after acquiring an additional 9,385 shares during the last quarter. Finally, Van ECK Associates Corp boosted its stake in shares of RxSight by 46.7% during the fourth quarter. Van ECK Associates Corp now owns 3,265 shares of the company's stock valued at $112,000 after acquiring an additional 1,040 shares during the last quarter. Institutional investors and hedge funds own 78.78% of the company's stock.

Insider Activity at RxSight

In other RxSight news, Director Tamara Fountain sold 7,000 shares of the firm's stock in a transaction that occurred on Wednesday, March 12th. The stock was sold at an average price of $25.71, for a total transaction of $179,970.00. Following the completion of the sale, the director now owns 24,793 shares in the company, valued at $637,428.03. This trade represents a 22.02% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Company insiders own 9.36% of the company's stock.

RxSight Stock Performance

Shares of NASDAQ:RXST traded down $0.03 during mid-day trading on Tuesday, hitting $16.30. 220,614 shares of the company traded hands, compared to its average volume of 676,755. The firm has a market cap of $662.18 million, a P/E ratio of -19.63 and a beta of 1.32. RxSight, Inc. has a 52-week low of $12.53 and a 52-week high of $64.50. The firm's 50 day simple moving average is $17.89 and its 200 day simple moving average is $29.71.

RxSight (NASDAQ:RXST - Get Free Report) last announced its earnings results on Wednesday, May 7th. The company reported ($0.03) EPS for the quarter, meeting the consensus estimate of ($0.03). The business had revenue of $37.90 million for the quarter, compared to the consensus estimate of $38.74 million. RxSight had a negative return on equity of 14.00% and a negative net margin of 23.92%. The company's revenue was up 28.5% on a year-over-year basis. During the same period last year, the business posted ($0.25) EPS. Equities research analysts expect that RxSight, Inc. will post -0.7 EPS for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently weighed in on RXST shares. JPMorgan Chase & Co. reiterated an "underweight" rating and set a $17.00 target price (down from $40.00) on shares of RxSight in a research report on Friday, April 4th. Stifel Nicolaus cut their price objective on RxSight from $33.00 to $28.00 and set a "hold" rating on the stock in a report on Wednesday, March 19th. Bank of America restated an "underperform" rating and issued a $22.00 price objective (down from $36.00) on shares of RxSight in a report on Thursday, April 3rd. UBS Group downgraded RxSight from a "buy" rating to a "neutral" rating and cut their price objective for the stock from $45.00 to $16.00 in a report on Wednesday, April 9th. Finally, Wells Fargo & Company upgraded RxSight from an "equal weight" rating to an "overweight" rating and raised their price objective for the stock from $17.00 to $25.00 in a report on Monday. Two investment analysts have rated the stock with a sell rating, three have assigned a hold rating and five have issued a buy rating to the company. According to data from MarketBeat.com, RxSight currently has an average rating of "Hold" and a consensus target price of $37.90.

About RxSight

RxSight, Inc, a commercial-stage medical device company, engages in the research and development, manufacture, and sale of light adjustable intraocular lenses (LAL) used in cataract surgery in the United States and internationally. It offers RxSight system that enables doctors to customize and enhance the visual acuity for patients after cataract surgery.